Massachusetts Wealth Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
Other funds holding PBE
Massachusetts Wealth Management's PBE Position: Q3 2026 in Review
Massachusetts Wealth Management reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 1.8% in Q3 2026, selling an estimated $30.5K and leaving 17,459 shares worth $1.7M. The position accounts for 0.68% of the portfolio, ranked #54.
Massachusetts Wealth Management first reported a position in PBE in Q4 2022 and has held it in 16 quarters since. 123 funds tracked by Wall St. Rank hold PBE as of Q3 2026.
- Massachusetts Wealth Management held 17,459 shares of Invesco Biotechnology & Genome ETF worth $1.7M as of Q3 2026.
- Massachusetts Wealth Management sold 325 Invesco Biotechnology & Genome ETF shares in Q3 2026, an estimated $30.5K.
- Invesco Biotechnology & Genome ETF made up 0.68% of Massachusetts Wealth Management's portfolio in Q3 2026, its #54 holding.
- Massachusetts Wealth Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2022 and has held it in 16 quarters since.
- 123 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.
Based on Massachusetts Wealth Management's 13F filing for Q3 2026, filed 21 Oct 2026.